FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index; 22 of the 48 sources its claims cite were checked for support.
Abstract
Prostate cancer progression to the androgen-independent (AI) state involves acquisition of pathways that allow tumor growth under low-androgen conditions. We hypothesized that expression of molecular chaperones that modulate androgen binding to AR might be altered in prostate cancer and contribute to progression to the AI state. Here, we report that the Hsp90 cochaperone FKBP51 is upregulated in LAPC-4 AI tumors grown in castrated mice and describe a molecular mechanism by which FKBP51 regulates AR activity. Using recombinant proteins, we show that FKBP51 stimulates recruitment of the cochaperone p23 to the ATP-bound form of Hsp90, forming an FKBP51-Hsp90-p23 superchaperone complex. In cells, FKBP51 expression promotes superchaperone complex association with AR and increases the number of AR molecules that undergo androgen binding. FKBP51 stimulates androgen-dependent transcription and cell growth, and FKBP51 is part of a positive feedback loop that is regulated by AR and androgen. Finally, depleting FKBP51 levels by short hairpin RNA reduces the transcript levels of genes regulated by AR and androgen. Because the superchaperone complex plays a critical role in determining the ligand-binding competence and transcription function of AR, it provides an attractive target for inhibiting AR activity in prostate cancer cells.
Overview
CoChat Summary
TL;DR
FKBP51 is overexpressed in an androgen-independent LAPC-4 prostate cancer xenograft model and promotes assembly of an FKBP51-Hsp90-p23 superchaperone complex that increases the number of androgen-bound AR molecules. This provides a feed-forward mechanism for AR signaling and growth under low-androgen conditions, and suggests the superchaperone complex as a therapeutic target.
Key findings
- FKBP51 protein was elevated about threefold and FKBP51 mRNA 7- to 10-fold in LAPC-4 AI tumors grown in castrated mice versus AD tumors; S100P was upregulated 6- to 15-fold, and PSA was slightly higher in two of three AI xenografts.
- FKBP51 enhanced androgen-stimulated AR transcription from PSA, probasin, MMTV, and synthetic ARE reporters, while inhibiting dexamethasone-stimulated GR transcription; FK506 blocked FKBP51 enhancement of AR activity.
- FKBP51 promoted formation of an FKBP51-Hsp90-p23 ternary complex; assembly required ATP or AMP-PNP but not hydrolysis, was inhibited by geldanamycin and FK506, and required the AR ligand-binding domain for AR association.
- FKBP51 expression increased androgen-binding sites by 38% without changing AR levels or affinity, approximately doubled the PP2A/AR ratio in an androgen-bound AR assay, and FKBP51 knockdown reduced KLK2, PSA, and S100P transcripts; FKBP51 also gave a growth advantage at 50 pM R1881 (P < 0.001).
Methods
- LAPC-4 xenografts were grown in intact or castrated scid mice; prostate cancer cell lines PC-3 (AR-negative), LNCaP, and CWR22Rv1 (AR-positive) were used, with lentiviral FKBP51 overexpression or shRNA knockdown.
- AR activity was measured by dual-luciferase reporter assays and real-time PCR for endogenous AR-regulated genes; chaperone complexes were analyzed by immunoprecipitation/immunoblotting and by gel filtration with recombinant FKBP51, Hsp90, and p23.
- Androgen binding was measured by whole-cell [3H]R1881 binding and a PP2A-AR coimmunoprecipitation assay; growth was measured by MTT assay, with Student t tests and nonlinear regression for Bmax/Kd.
Limitations
- The paper states no explicit limitations section.
- Evident from the text: the mechanistic work relies heavily on overexpression in AR-negative PC-3 cells and recombinant proteins, and the in vivo evidence is limited to expression differences in LAPC-4/CWR22 xenografts rather than direct FKBP51 manipulation in tumors.
- The paper notes that FKBP51 overexpression was not detected in a previous microarray analysis of LAPC-4 xenografts, and that FKBP51 knockout mice lack overt androgen-signaling defects, leaving the normal physiological contribution of FKBP51 unclear.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 3 Not valid · 21 Not checked · 88 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Because the FKBP51 knockout mouse does not display overt defects in androgen signaling (4, 37), the contribution of FKBP51 to AR function has been unclear.”
What the sources say
- Could not verifycites [4] 4. Cheung-Flynn, J., V. Prapapanich, M. B. Cox, D. L. Riggs, C. Suarez-Quian, and D. F. Smith. 2005. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 19: 1654-1666. sourceExperimental — accuracy not yet measured
The “52KO Mice” section describes an FKBP52 knockout with reproductive defects, not an FKBP51 knockout. Searches for FKBP51, Fkbp5, and 51KO found no passage in our copy addressing whether FKBP51-knockout mice have overt defects in androgen signaling. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [37] 37. Yong, W., Z. Yang, S. Periyasamy, H. Chen, S. Yucel, W. Li, L. Y. Lin, I. M. Wolf, M. J. Cohn, L. S. Baskin, E. R. Sanchez, and W. Shou. 2007. Essential role for cochaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 282: 5026-5036. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reintroduction of AR into PC-3 cells activates the endogenous FKBP51 gene, an observation that is consistent with AR regulation of FKBP51 expression (11).”
What the sources say
- Supportedcites [11] 11. Kesler, C. T., D. Gioeli, M. R. Conaway, M. J. Weber, and B. M. Paschal. 2007. Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol. Endocrinol. 21: 2071-2084. source
The results passage on AR activity reports that AR was expressed in PC3 cells and that FKBP51 expression was activated when the cells were treated with R1881. The Fig. 5 caption also identifies FKBP51 mRNA induction after AR expression and R1881 addition; the experiment therefore supports the claim under androgen-treated conditions. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“FKBP51 negatively regulates GR and PR activity by reducing hormone binding affinity (6, 9).”
What the sources say
- Not checked — no full text of the sourcecites [6] 6. Denny, W. B., D. L. Valentine, P. D. Reynolds, D. F. Smith, and J. G. Scammell. 2000. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 141: 4107-4113. source
- Partly supportedcites [9] 9. Hubler, T. R., W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell. 2003. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 144: 2380-2387. sourceExperimental — accuracy not yet measured
The introduction states that squirrel monkey FKBP51 lowers hormone-binding affinity in the GR complex. The overexpression results show reduced PR responsiveness in HepG2 cells, but do not establish that reduced PR hormone-binding affinity is the mechanism; the Discussion instead suggests an interaction with hsp90. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“a quantitative coimmunoprecipitation assay developed in our laboratory (35) that discriminates between androgen-free and androgen-bound forms of AR”
What the sources say
- Supportedcites [35] 35. Yang, C.-S., H.-W. Xin, J. B. Kelley, A. Spencer, D. L. Brautigan, and B. M. Paschal. 2007. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol. Cell. Biol. 27: 3390-3404. source
The Discussion states that the AR–PP2A co-IP assay tests whether AR adopts an androgen-bound conformation. It also reports that PP2A release accompanies AR’s return to the androgen-free conformation, supporting the assay’s ability to distinguish the two forms. Page numbers are unavailable in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Mutations in the TPR domain that disrupt binding to Hsp90, described originally by Chinkers and associates in PP5 (29), were also constructed (M2).”
What the sources say
- Supportedcites [29] 29. Russell, L. C., S. R. Whitt, M. S. Chen, and M. Chinkers. 1999. Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90. J. Biol. Chem. 274: 20060-20063. source
The citation identifies the original PP5 mutations, not the citing authors’ FKBP51 M2 construct. The Results report that mutations in the PP5 TPR domain disrupted Hsp90 binding, matching the work the citing sentence attributes to this source. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
88 more claims · 1 with their cited sources checked
Create a free account to see all 129 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relative activities of the FKBP51-bound and FKBP52-bound androgen receptors differ from that observed for the glucocorticoid and progesterone receptors such that a positive-feedback expression process can arise under pathological conditions which appears to often substantially contribute to the metastatic phase of prostate cancer [10–12].”
From Differential conformational dynamics in the closely homologous FK506-binding domains of FKBP51 and FKBP52 (2014) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“studies have shown that the FK506 anti-proliferative effect is mediated by FKBP51, rather than FKBP52 [24, 25].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In LNCaP cells, treatment with FK506 inhibited the ligand-induced activity of AR at both reporter and endogenous genes by a mechanism that appears to reduce the intrinsic hormone-binding function of the receptor [24, 25].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“treatment of LNCaP prostate cancer cells with geldanamycin, or its derivative 17-AAG, reduced AR protein stability, hormone-binding function and transcriptional activity [24, 54].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the two most recent findings demonstrate that FKBP51 is nearly essential for androgen-induced growth of two different prostate cancer cell lines [24, 25].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“Finally, the M1, M2, and M1/M2 mutant forms have reduced activity in the PP2A-AR interaction assay, which is a readout of the number of AR molecules that are bound with androgen (Fig. 8C).”
§ RESULTS
“(D) Analysis of mutant forms of FKBP51 by using the PP2A-AR to assess the effect on androgen binding to AR.”
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 5×
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
BackgroundMethodInfluentialSteroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Self-citationStructure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex
Ali, M. M. U., Roe, S. M., Vaughan, C. K., Meyer, P., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2006) · Nature · doi:10.1038/nature04716 · Cited by 962 · cited 3×
“Crystallographic analysis revealed that p23 recognizes the ATP-bound, closed conformation of Hsp90; a major contact surface for p23 is formed by “lid” closure of Hsp90 (1).”
BackgroundSteroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones
Pratt, W. B. (1997) · Endocrine Reviews · doi:10.1210/er.18.3.306 · Cited by 641
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Disassembly of Transcriptional Regulatory Complexes by Molecular Chaperones
Freeman, B. C., & Yamamoto, K. R. (2002) · Science · doi:10.1126/science.1073051 · Cited by 400 · cited 1×
“function, including transcription complex disassembly (8).”
Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., et al. (1997) · Nature Medicine · doi:10.1038/nm0497-402 · Cited by 399
The Hsp90‐binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo
Riggs, D. L., Roberts, P. J., Chirillo, S. C., Cheung‐Flynn, J., Prapapanich, V., Ratajczak, T., Gaber, R., Picard, D., & Smith, D. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg108 · Cited by 353
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307 · cited 1×
“Highdose 17-AAG, however, causes skeletal complications and increases Hsp70 levels, the latter of which may promote tumor resistance to therapy (23, 25).”
Background
Cited by
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
“One coactivator, FKBP51, which is also an AR target gene, was found to be upregulated in relapsed LAPC-4 tumors grown in castrate mice (53).”
BackgroundJackson, S. E. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_356 · Cited by 338
“FKBP51, on the other hand, appears to play no role in male fertility but is a positive regulator of androgen-mediated growth of prostate cancer [264, 265].”
BackgroundAndrogen receptor signaling in prostate cancer
Culig, Z., & Santer, F. R. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9474-0 · Cited by 283
“A cochaperone of Hsp90, FK506-binding protein, augments AR activity in LAPC4 cells [94].”
BackgroundFKBP51 and FKBP52 in signaling and disease
Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T., & Cox, M. B. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.08.001 · Cited by 266
“[42,43].”
Versatile TPR domains accommodate different modes of target protein recognition and function
Allan, R. K., & Ratajczak, T. (2011) · Cell Stress and Chaperones · doi:10.1007/s12192-010-0248-0 · Cited by 247
Steroid up-regulation of FKBP51 and its role in hormone signaling
Jääskeläinen, T., Makkonen, H., & Palvimo, J. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.04.006 · Cited by 167
Fries, G., Gassen, N., & Rein, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122614 · Cited by 166
“It should be mentioned, though, that some of the effects of FK506 have been ascribed specifically to the inhibition of FKBP51, in particular by blocking the AR and thereby inhibiting prostate cancer cell growth [229,230].”
BackgroundMechanisms of Therapeutic Resistance in Prostate Cancer
Nakazawa, M., Paller, C., & Kyprianou, N. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0568-7 · Cited by 154
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150
De Leon, J. T., Iwai, A., Feau, C., Garcia, Y., Balsiger, H. A., Storer, C. L., Suro, R. M., Garza, K. M., Lee, S., Sang Kim, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105160108 · Cited by 132
“However, unlike PSA, FKBP51 is a component of SHR–chaperone complexes (15) and has recently been shown to promote AR function in LNCaP cells similar to FKBP52 (16).”
BackgroundFK506-Binding Proteins and Their Diverse Functions
Tong, M., & Jiang, Y. (2015) · Current Molecular Pharmacology · doi:10.2174/1874467208666150519113541 · Cited by 156
“FKBP51 has been found to associate androgen receptor (AR) and overexpression of FKBP51 stimulates AR transcriptional activity and cell proliferation [187].”
BackgroundMolecular and cellular mechanisms of castration resistant prostate cancer (Review)
Huang, Y., Jiang, X., Liang, X., & Jiang, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8123 · Cited by 191
“For example, FKBP51, as an AR target gene and a co-activator of AR, was determined to be upregulated in relapsed LAPC-4 tumors that were grown in castrated mice (57).”
BackgroundThe role of FKBP5 in cancer aetiology and chemoresistance
Li, L., Lou, Z., & Wang, L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606014 · Cited by 143
“Recently, Ni et al (2010) showed that FKBP5 stimulates the recruitment of cochaperone p23 to the ATP-bound form of Hsp90, forming an FKBP5 –Hsp90– p23 superchaperone complex, which stimulates androgen-dependent transcription activation and cell growth.”
BackgroundA New Anti-Depressive Strategy for the Elderly: Ablation of FKBP5/FKBP51
O'Leary, J. C., Dharia, S., Blair, L. J., Brady, S., Johnson, A. G., Peters, M., Cheung-Flynn, J., Cox, M. B., de Erausquin, G., Weeber, E. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024840 · Cited by 122
“These include prostate cancer [25], and neurodegenerative diseases, specifically tauopathies [17].”
BackgroundHähle, A., Merz, S., Meyners, C., & Hausch, F. (2019) · Biomolecules · doi:10.3390/biom9010035 · Cited by 119
“Contrary to GR, where FKBP51 has repeatedly been described as an inhibitory factor, two studies in 2010 reported an activation of AR by FKBP51 [74,75].”
BackgroundDifferential Impact of Tetratricopeptide Repeat Proteins on the Steroid Hormone Receptors
Schülke, J.-P., Wochnik, G. M., Lang-Rollin, I., Gassen, N. C., Knapp, R. T., Berning, B., Yassouridis, A., & Rein, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011717 · Cited by 105
“Very recently, a stimulatory effect of FKBP51 on AR has been reported in prostate cancer cells [82,83].”
BackgroundThe prospect of FKBP51 as a drug target
Schmidt, M. V., Paez‐Pereda, M., Holsboer, F., & Hausch, F. (2012) · ChemMedChem · doi:10.1002/cmdc.201200137 · Cited by 99
Biological Actions of the Hsp90-binding Immunophilins FKBP51 and FKBP52
Zgajnar, N., De Leo, S., Lotufo, C., Erlejman, A., Piwien-Pilipuk, G., & Galigniana, M. (2019) · Biomolecules · doi:10.3390/biom9020052 · Cited by 94
“Accordingly, the overexpression of FKBP51 favours prostate cancer cell growth and impairs the effectiveness of antiandrogen therapies, for example, treatments with bicalutamide, that is frequently used in patients undergoing androgen ablation therapy [94].”
BackgroundChaperoning steroidal physiology: Lessons from mouse genetic models of Hsp90 and its cochaperones
Sanchez, E. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.11.006 · Cited by 94
“In contrast to its apparent neutrality in male fertility, FKBP51 is a powerful positive regulator of androgen-mediated growth of prostate cancer cells [70,71].”
BackgroundFKBP51 – a selective modulator of glucocorticoid and androgen sensitivity
Stechschulte, L. A., & Sanchez, E. R. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.04.012 · Cited by 92
“Two recent reports showed that treatment of LNCaP prostate cancer cells with geldanamycin, or its derivative 17-AAG, reduced AR protein stability, hormone-binding function, and transcriptional activity [24 ,54].”
BackgroundIntrinsic disorder in the androgen receptor: identification, characterisation and drugability
McEwan, I. J. (2011) · Molecular BioSystems · doi:10.1039/c1mb05249g · Cited by 86
Lee, K., Thwin, A. C., Nadel, C. M., Tse, E., Gates, S. N., Gestwicki, J. E., & Southworth, D. R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.023 · Cited by 76
Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance
Zhang, J., Li, H., Liu, Y., Zhao, K., Wei, S., Sugarman, E. T., Liu, L., & Zhang, G. (2022) · Cells · doi:10.3390/cells11182778 · Cited by 81
Hsp90, the Concertmaster: Tuning Transcription
Khurana, N., & Bhattacharyya, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00100 · Cited by 82
“Recent study shows that Hsp90 and its co-chaperone FKBP51 also promotes hormone-independent nuclear localization of androgen receptor in prostate cancer cells (10) and thereby plays a critical role in progression of prostate cancer.”
BackgroundRegulation of masculinization: androgen signalling for external genitalia development
Matsushita, S., Suzuki, K., Murashima, A., Kajioka, D., Acebedo, A. R., Miyagawa, S., Haraguchi, R., Ogino, Y., & Yamada, G. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0008-y · Cited by 76
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer
Cano, L. Q., Lavery, D. N., & Bevan, C. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.023 · Cited by 81
FKBP family proteins as promising new biomarkers for cancer
Solassol, J., Mangé, A., & Maudelondé, T. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.012 · Cited by 75
Molecular Cochaperones: Tumor Growth and Cancer Treatment
Calderwood, S. K. (2013) · Scientifica · doi:10.1155/2013/217513 · Cited by 68
“As mentioned above-immunophilins appear to be significant in hormone-dependent cancer, and FKBP1 in particular is enriched in prostate cancer as opposed to benign tumors and stimulates androgen-dependent transcription and growth [164–166, 170, 171].”
BackgroundEvaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52
Gopalakrishnan, R., Kozany, C., Gaali, S., Kress, C., Hoogeland, B., Bracher, A., & Hausch, F. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201746x · Cited by 64
Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90
Bracher, A., Kozany, C., Thost, A.-K., & Hausch, F. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911013862 · Cited by 62
“Recently, FKBP51 has also been shown by two independent groups to enhance androgen receptor signalling in prostate cancer cell lines in an FK506-sensitive manner (Ni et al., 2010; Periyasamy et al., 2010).”
BackgroundConstitutive Activity of the Androgen Receptor
Chan, S. C., & Dehm, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-417197-8.00011-0 · Cited by 71
Gillis, J. L., Selth, L. A., Centenera, M. M., Townley, S. L., Sun, S., Plymate, S. R., Tilley, W. D., & Butler, L. M. (2013) · Oncotarget · doi:10.18632/oncotarget.975 · Cited by 61
“Plasmid constructs harbouring full-length AR with somatic missense mutations were created from pCMV-AR by PCR-based megaprimer in vitro mutagenesis as previously described [33].”
MethodKaiser, E., Böhm, N., Ernst, K., Langer, S., Schwan, C., Aktories, K., Popoff, M. R., Fischer, G. S., & Barth, H. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2012.01788.x · Cited by 58
“The active site of FKBP51 was found to be implicated as a positive regulator in androgen receptor signalling in prostate cancer cell lines because FK506 can block androgen-induced cell proliferation (Periyasamy et al., 2007; Ni et al., 2010).”
BackgroundKollara, A., & Brown, T. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1000-y · Cited by 58
FKBP51 regulation of AKT/protein kinase B phosphorylation
Wang, L. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.008 · Cited by 55
Wang, L., Song, G., Chang, X., Tan, W., Pan, J., Zhu, X., Liu, Z., Mao, Q., Yu, J., & Han, B. (2014) · Oncogene · doi:10.1038/onc.2014.401 · Cited by 51
InterAKTions with FKBPs - Mutational and Pharmacological Exploration
Fabian, A.-K., März, A., Neimanis, S., Biondi, R. M., Kozany, C., & Hausch, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057508 · Cited by 48
“Several studies have shown that FKBP51 is upregulated in several cancers and that it can promote the proliferation of many cancer cell lines [25,38-41].”
BackgroundThe Stress Response Mediator ATF3 Represses Androgen Signaling by Binding the Androgen Receptor
Wang, H., Jiang, M., Cui, H., Chen, M., Buttyan, R., Hayward, S. W., Hai, T., Wang, Z., & Yan, C. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00159-12 · Cited by 47
FKBPs in chromatin modification and cancer
Yao, Y., Liang, Y., Huang, H.-H., & Yang, W. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.005 · Cited by 41
Lagadari, M., Zgajnar, N. R., Gallo, L. I., & Galigniana, M. D. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.05.002 · Cited by 38
RetractedING3 promotes prostate cancer growth by activating the androgen receptor
Nabbi, A., McClurg, U. L., Thalappilly, S., Almami, A., Mobahat, M., Bismar, T. A., Binda, O., & Riabowol, K. T. (2017) · BMC Medicine · doi:10.1186/s12916-017-0854-0 · Cited by 44
“FKBP5, induced by AR via several AREs, modulates the AR pathway through forming a positive feedback loop [35, 50, 51] as noted in Fig.”
BackgroundSun, N., Huang, S., Chang, P., Lu, H., & Chao, C. C. ‐. (2014) · Oncotarget · doi:10.18632/oncotarget.2654 · Cited by 37
The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL
McKeen, H. D., Brennan, D. J., Hegarty, S. M., Lanigan, F. T., Jirström, K., Byrne, C., Yakkundi, A., McCarthy, H. O., Gallagher, W. M., & Robson, T. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390663 · Cited by 38
Donley, C., McClelland, K., McKeen, H. D., Nelson, L., Yakkundi, A., Jithesh, P. V., Burrows, J. F., McClements, L., Valentine, A., Prise, K. M., et al. (2013) · Oncogene · doi:10.1038/onc.2013.306 · Cited by 40
The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer
Romano, S., Sorrentino, A., Pace, A. L. D., Nappo, G., Mercogliano, C. J., & Romano, M. F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798194333 · Cited by 44
“Depleting FKBP51 levels by short hairpin RNA reduced the transcript levels of genes regulated by AR and androgen, suggesting the importance of this immunophilin in determining the ligandbinding competence and transcription function of AR [55].”
BackgroundGene expression regulation by heat-shock proteins: the cardinal roles of HSF1 and Hsp90
Mazaira, G. I., Daneri-Becerra, C., Zgajnar, N. R., Lotufo, C. M., & Galigniana, M. D. (2017) · Biochemical Society Transactions · doi:10.1042/bst20170335 · Cited by 39
SGTA: A New Player in the Molecular Co-Chaperone Game
Philp, L., Butler, M. S., Hickey, T. E., Butler, L. M., Tilley, W. D., & Day, T. K. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0151-0 · Cited by 37
“In comparison, FKBP51, which in vitro enhances AR-dependent transcription and ligand responsiveness [61], does not produce an apparent male or female physiological phenotype in a knockout mouse model [97].”
BackgroundJC, O. L., Zhang, B., Koren, J., Blair, L. J., & Dickey, C. A. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152731131200121 · Cited by 43
“All three complexes do require Hsp90 for FKBP51 to have an effect, as Hsp90 was found necessary to be bound to FKBP51 for it to have its inhibitory action on GR [32], PR [31], and its activating action on AR [34].”
BackgroundFunctions of the Hsp90-Binding FKBP Immunophilins
Guy, N. C., Garcia, Y. A., Sivils, J. C., Galigniana, M. D., & Cox, M. B. (2015) · Subcellular Biochemistry · doi:10.1007/978-3-319-11731-7_2 · Cited by 35
“demonstrated that FKBP51 stimulates chaperone complex association with AR, which further enhances AR ligand binding and androgen-dependent transcription and cell growth, resulting in an ultra-short positive feedback loop (Ni et al. 2010).”
BackgroundWu, D., Tao, X., Chen, Z., Han, J., Jia, W.-J., Zhu, N., Li, X., Wang, Z., & He, Y. (2015) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2015.12.045 · Cited by 37
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
Zhang, H., Yi, Z., Xing, Z., Sah, R. K., Hu, J., & Hu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113521 · Cited by 46
Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis
Kawahara, T., Kashiwagi, E., Li, Y., Zheng, Y., Miyamoto, Y., Netto, G. J., Ishiguro, H., & Miyamoto, H. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22265 · Cited by 36
“In particular, immunophilins that CsA and FK506 bind have been shown to regulate assembly of the chaperone complex with androgen receptor (AR) and hsp70 and thereby inhibit AR activity [29], while AR signals are likely essential for urothelial carcinogenesis [18,21,30].”
BackgroundDrug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
Yehya, A., Ghamlouche, F., Zahwe, A., Zeid, Y., Wakimian, K., Mukherji, D., & Abou-Kheir, W. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.15 · Cited by 37
Pleiotropic roles in cancer biology for multifaceted proteins FKBPs
Romano, S., D’Angelillo, A., & Romano, M. F. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.01.004 · Cited by 36
Steroid Receptor-Associated Immunophilins: A Gateway to Steroid Signalling.
Ratajczak, T., Cluning, C., & Ward, B. K. (2015) · Europe PMC (PubMed Central) · Cited by 41
FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells
Maeda, K., Habara, M., Kawaguchi, M., Matsumoto, H., Hanaki, S., Masaki, T., Sato, Y., Matsuyama, H., Kunieda, K., Nakagawa, H., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13030 · Cited by 32
Glucocorticoid receptor cofactors as therapeutic targets
Simons, S. S. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.08.001 · Cited by 34
Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy
Shah, K., & Bradbury, N. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3899 · Cited by 32
“Gene-specific forward and reverse primers (Supplementary Table 1) used have been reported in earlier studies [60, 61].”
Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
Cai, Z., Chen, W., Zhang, J., & Li, H. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1964-0 · Cited by 35
FK506 Binding Protein 10 Is Overexpressed and Promotes Renal Cell Carcinoma
Ge, Y., Xu, A., Zhang, M., Xiong, H., Lu, F., Zhang, X., Liu, C., & Wu, S. (2016) · Urologia Internationalis · doi:10.1159/000448338 · Cited by 29
The activity of the glucocorticoid receptor is regulated by SUMO conjugation to FKBP51
Antunica-Noguerol, M., Budziñski, M. L., Druker, J., Gassen, N. C., Sokn, C., Senin, S. A., Aprile-Garcia, F., Holsboer, F., Rein, T., Liberman, A. C., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.44 · Cited by 34
“Remarkably, recruitment of FKBP51 as a cochaperone to Hsp90 protein complexes modulates the activity of other nuclear receptors, besides GR.42,43 It is thus likely that SUMO conjugation to FKBP51 may impact on their activity as well.”
BackgroundInfluentialUnraveling the Role of Peptidyl-Prolyl Isomerases in Neurodegeneration
Gérard, M., Deleersnijder, A., Demeulemeester, J., Debyser, Z., & Baekelandt, V. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8184-2 · Cited by 36
Jirawatnotai, S., Sharma, S., Michowski, W., Suktitipat, B., Geng, Y., Quackenbush, J. F., Elias, J. E., Gygi, S. P., Wang, Y. E., & Siciński, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946850 · Cited by 30
“Thus, FKBP5 was shown to stimulate androgen-dependent transcriptional activation and to promote prostate cancer growth.(36) Ectopic overexpression of FKBP5 was demonstrated to increase radioresistance of melanoma cells.”
BackgroundFKBP38-Bcl-2 interaction: a novel link to chemoresistance
Choi, B., & Yoon, H. S. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.04.013 · Cited by 30
Armstrong, H., Koay, Y. C., Irani, S., Das, R., Nassar, Z. D., BioResource, T. A. P. C., Selth, L. A., Centenera, M. M., McAlpine, S. R., & Butler, L. M. (2016) · The Prostate · doi:10.1002/pros.23239 · Cited by 28
“The co-chaperone p23, which stabilizes the closed HSF-1 bound state of Hsp90, is downregulated in response to SM253 and SM258, suggesting one mechanism by which these compounds act to inhibit heat shock protein induction [60,61].”
BackgroundFKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer
Habara, M., Sato, Y., Goshima, T., Sakurai, M., Imai, H., Shimizu, H., Katayama, Y., Hanaki, S., Masaki, T., Morimoto, M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110256119 · Cited by 29
“FKBP52 positively regulates the function of these nuclear receptors (24–28), whereas FKBP51 negatively regulates the activity of GR (29) and PR (30), and positively regulates AR (28, 31).”
BackgroundBiron, É., & Bédard, F. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.006 · Cited by 28
Transcriptional activity of c-Jun is critical for the suppression of AR function
Hsu, C.-C., & Hu, C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.004 · Cited by 27
“We also thank Dr. Bryce M. Paschal (University of Virginia Charlottesville, VA) for generously sharing luciferase reporters driven by MMTV promoter (MMTV-Luc), probasin promoter (ARR3tk-Luc) or synthetic androgen response elements (PGL3-ARE-Luc) (Ni et al., 2010).”
BackgroundNew Opportunities for Targeting the Androgen Receptor in Prostate Cancer
Centenera, M. M., Selth, L. A., Ebrahimie, E., Butler, L. M., & Tilley, W. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030478 · Cited by 30
“The intrinsic ATPase activity of HSP90 together with the PPIase activity of the immunophilins fold AR into its functionally mature state by opening the AR ligand-binding pocket to make it accessible to androgens (Fang et al. 1996; Grenert et al. 1999; Ni et al. 2010).”
BackgroundPozas, J., Rodríguez, S. Á., Albarrán, V., Burgos, J., Santoni, M., Kopp, R. M., Molina‐Cerrillo, J., & Alonso‐Gordoa, T. (2022) · Cancers · doi:10.3390/cancers14246071 · Cited by 31
“This leads to the formation of a superchaperone complex that associates with AR, stimulating androgen binding [84].”
BackgroundMustafi, S. M., LeMaster, D. M., & Hernández, G. (2014) · Biochemical Journal · doi:10.1042/bj20140232 · Cited by 25
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Maximov, P. Y., Abderrahman, B., Curpan, R. F., Hawsawi, Y. M., Fan, P., & Jordan, V. C. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0416 · Cited by 29
“1998), FKBP51 stabilizes the AR with HSP90 heat-shock protein complex and facilitates the binding of androgens (Ni et al. 2010), and TRIM24 increases AR transcriptional activity (Groner et al.”
BackgroundAdvances in PARP Inhibitors for Prostate Cancer
Tisseverasinghe, S., Bahoric, B., Anidjar, M., Probst, S., & Niazi, T. M. (2023) · Cancers · doi:10.3390/cancers15061849 · Cited by 30
Dilworth, D., Gudavicius, G., Leung, A., & Nelson, C. J. (2012) · Biochemistry and Cell Biology · doi:10.1139/o11-045 · Cited by 26
Tetratricopeptide Repeat Domain 9A Negatively Regulates Estrogen Receptor Alpha Activity
Shrestha, S., Sun, Y., Lufkin, T., Kraus, P., Or, Y., Garcia, Y. A., Guy, N. C., Ramos, P. A., Cox, M. B., Tay, F., et al. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.9311 · Cited by 25
“In contrast, FKBP51 over-expression promoted ERα activity in the presence and absence of E2, which is consistent with the previous report [34].”
ResultInhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
Pollock, J. A., Wardell, S. E., Parent, A. A., Stagg, D. B., Miner, S. J., Alley, H. M., Chao, C., Lawrence, S. A., Stice, J. P., Spasojević, I., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2131 · Cited by 21
Agam, G., Atawna, B., Damri, O., & Azab, A. N. (2024) · Cells · doi:10.3390/cells13100801 · Cited by 26
“Hence, downregulation of its levels results in reduced transcript levels of genes regulated by AR and androgen [76].”
BackgroundInfluentialRegulation of FKBP51 and FKBP52 functions by post-translational modifications
Daneri-Becerra, C., Zgajnar, N. R., Lotufo, C. M., Ramos-Hryb, A. B., Piwien‐Pilipuk, G., & Galigniana, M. D. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190334 · Cited by 24
Maylin, Z. R., Nicolescu, R. C. B., Pandha, H., & Asim, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101115 · Cited by 22
Biological relevance of Hsp90‐binding immunophilins in cancer development and treatment
Mazaira, G. I., Camisay, M. F., Leo, S. A. D., Erlejman, A. G., & Galigniana, M. D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29509 · Cited by 25
“Treatments with FK506 have been shown to inhibit the proliferation of prostate cancer cells and this fact was assigned to blockade of the enhancing effect of FKBP51 on the AR in these cells.(58,76) It has also been reported a physical association of FKBP51 with the Hsp90 bound kinase upstream of IjB, IKK via its IKK a…”
BackgroundArmstrong, C. M., & Gao, A. C. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.001 · Cited by 24
“The AR co-activator FKBP51 has been observed to be upregulated in relapsed LAPC-4 tumor xenografts in castrated mice resulting in increased activation of the AR in response to ligand [73].”
BackgroundFKBP51 regulates cell motility and invasion via RhoA signaling
Takaoka, M., Ito, S., Miki, Y., & Nakanishi, A. (2016) · Cancer Science · doi:10.1111/cas.13153 · Cited by 23
Erlejman, A. G., Lagadari, M., Harris, D. C., Cox, M. B., & Galigniana, M. D. (2014) · Current Protein and Peptide Science · doi:10.2174/1389203715666140331113753 · Cited by 25
The physiology of stress and the human body’s response to stress
Lee, R. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823039-8.00017-4 · Cited by 28
Kinase Modulation of Androgen Receptor Signaling: Implications for Prostate Cancer
Shah, K., & Bradbury, N. A. (2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1023 · Cited by 22
de Azevedo, H. F. Z., Fujita, A., Bando, S. Y., Iamashita, P., & Moreira‐Filho, C. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110934 · Cited by 19
FKBPL: a marker of good prognosis in breast cancer
Nelson, L., McKeen, H. D., Marshall, A., Mulrane, L., Starczynski, J., Storr, S. J., Lanigan, F. T., Byrne, C., Arthur, K., Hegarty, S. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3528 · Cited by 18
“FKBP51 is another FKBP which has been shown to play a role in steroid hormone signalling, where it displays both inhibitory [47] and stimulatory [48] roles.”
Ratajczak, T. (2015) · Current Molecular Pharmacology · doi:10.2174/1874467208666150519113639 · Cited by 18
Sex Differences in Depression Caused by Early Life Stress and Related Mechanisms
An, X., Guo, W., Wu, H., Fu, X., Li, M., Zhang, Y., Li, Y., Cui, R., Yang, W., Zhang, Z., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.797755 · Cited by 24
Kadry, M. O., & Megeed, R. M. A. (2023) · Gene Expression · doi:10.14218/ge.2023.00069 · Cited by 15
FKBP51 protects 661w cell culture from staurosporine-induced apoptosis.
Daudt, D., & Yorio, T. (2011) · PubMed Central · Cited by 18
Induction of FKBP51 by aldosterone in intestinal epithelium
Petrovich, E., Asher, C., & Garty, H. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.10.006 · Cited by 18
Structural and biochemical insights into FKBP51 as a Hsp90 co‐chaperone
Baischew, A., Engel, S., Geiger, T. M., Taubert, M. C., & Hausch, F. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30384 · Cited by 15
Soto, O. B., Ramirez, C. S., Koyani, R. D., Rodriguez‐Palomares, I. A., Dirmeyer, J. R., Grajeda, B. I., Roy, S., & Cox, M. B. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30406 · Cited by 15
AmotL2, IQGAP1, and FKBP51 Scaffold Proteins in Glioblastoma Stem Cell Niches
Rotoli, D., Díaz‐Flores, L., Gutiérrez, R., Morales, M., Ávila, J., & Martín-Vasallo, P. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211025480 · Cited by 13
Chu, Y.-W., Chien, C.-H., Sung, M., Chen, C.-W., & Chen, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234084 · Cited by 11
“FKBP5 can stimulate the formation of a FKBP5-Hsp90-p23 superchaperone complex, which promotes cell growth in prostate cancer via androgen receptor-mediated signaling [35].”
BackgroundMolecular signaling involving intrinsically disordered proteins in prostate cancer
Marasco, D., Russo, A., Manna, S. L., Novellino, E., & Malfitano, A. M. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.181817 · Cited by 13
Verkhivker, G. M. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c03464 · Cited by 13
Chaperones and ADP-Ribosylating Bacterial Toxins
Barth, H., & Ernst, K. (2016) · Springer eBooks · doi:10.1007/978-94-007-6725-6_7-1 · Cited by 11
Wang, L., Wojcieszak, J., Kumar, R., Zhao, Z., Sun, X., Xie, S., Winblad, B. G., & Pavlov, P. F. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03627-x · Cited by 13
“FKBP51 is also a positive regulator of AR [34, 35], linking its effects to gonadal hormone signaling.”
Background
Metadata
- Authors
- Ni, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M.
- Affiliations
- Center for Cell Signaling
- Departments of Microbiology
- University of Virginia (US)
- Mayo Clinic (US)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 30
- Issue
- 5
- Pages
- 1243-1253
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC2820886
- OpenAlex
- W2059122555
- Cited by
- 155
- References
- 37
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 11 · 2020: 4 · 2019: 8 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 16 · 2014: 15 · 2013: 14 · 2012: 9
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Cancer Institute (P01CA104106, R01CA124706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- FKBP51, HSP90, p23, androgen receptor, castration-resistant prostate cancer, androgen receptor signaling, androgen binding, positive feedback loop, molecular chaperones, prostate cancer progression, LAPC4 cells
- MeSH terms
- Prostaglandin-E Synthases, Tacrolimus Binding Protein 5, Animals, Base Sequence, Humans, Male, Models, Biological, Neoplasm Transplantation, Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Receptors, Androgen, Recombinant Proteins, Transplantation, Heterologous, Signal Transduction, Up-Regulation, Mice, SCID, DNA Primers, HSP90 Heat-Shock Proteins, Intramolecular Oxidoreductases, Tacrolimus Binding Proteins, Cell Line, Tumor, Multiprotein Complexes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.